RxDoctor Payments DataLook up a doctor →

Peter Hedera, MD

Neurology · Louisville, KYNPI 1518041615

Payments from drug & device makers

$421,813in general payments, 2019–2025

Across 431 payments — averaging $978.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$107K
  • Ipsen Pharma SAS$91K
  • MDD US Operations, LLC$60K
  • Ipsen Biopharmaceuticals, Inc$42K
  • AstraZeneca$33K
  • UCB SA$27K
  • plus $61K from 15 others
$16,529in research payments, 2019–2025

Across 6 payments — averaging $2754.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$16K
  • Avanir Pharmaceuticals, Inc.$490

What the payments were for

  • Consulting fees$84,06445%
  • Speaking & faculty fees$80,44843%
  • Travel & lodging$13,2277%
  • Food & beverage$7,6834%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$421,813 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$55,430
Medicare patients
224
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate101$543,172
AustedoDeutetrabenazine22$247,926
IngrezzaValbenazine Tosylate12$97,070
GocovriAmantadine Hcl28$83,379
Austedo XrDeutetrabenazine13$63,699
RytaryCarbidopa/Levodopa35$41,460
InbrijaLevodopa12$40,928
NourianzIstradefylline18$38,544
NeuproRotigotine16$21,048
Carbidopa15$17,290
Emgality PenGalcanezumab-Gnlm11$11,127
Carbidopa-Levodopa ErCarbidopa/Levodopa170$9,683
Carbidopa-LevodopaCarbidopa/Levodopa272$9,195
Entacapone21$6,112
Rasagiline Mesylate24$4,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$138$311,62635 claims
Neurocrine Biosciences, Inc.Ingrezza$107,280$97,07012 claims
MDD US Operations, LLCGocovri$60,320$83,37928 claims
Amneal Pharmaceuticals LLCRytary$414$41,46035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →